Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1629
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17789374 | ARGINASE INHIBITORS AND METHODS OF USE | Non-Final OA | MERCK SHARP & DOHME LLC |
| 19300296 | Additive for Food, Drink and Pharmaceutical Products to Improve Health and Well-Being | Non-Final OA | RB2 Enterprises, LLC |
| 19285330 | PHARMACEUTICAL COMPOSITION COMPRISING MELOXICAM | Non-Final OA | Mylan Laboratories LTD |
| 17616930 | ALTERNATIVE PROCESS FOR THE PREPARATION OF 4-PHENYL-5-ALKOXYCARBONYL-2-THIAZOL-2-YL-1,4-DIHYDROPYRIMIDIN-6-YL]METHYL]-3-OXO-5,6,8,8A-TETRAHYDRO-1H-IMIDAZO[1,5-A]PYRAZIN-2-YL]-CARBOXYLIC ACID | Final Rejection | Hoffmann-La Roche Inc. |
| 18035671 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | Non-Final OA | EBERHARD KARLS UNIVERSITÄT TÜBINGEN |
| 18030139 | METHODS OF TREATING HERPES VIRAL INFECTION WITH 4-PHENYLBUTYRATE (PBA) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Final Rejection | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 18301361 | METHODS FOR THE TREATMENT OF PRESBYOPIA | Non-Final OA | LENZ Therapeutics Operations, Inc. |
| 17642610 | DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 17797368 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | Final Rejection | Neurocrine Biosciences, Inc. |
| 18443904 | MEK-INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | Non-Final OA | ATRIVA THERAPEUTICS GMBH |
| 17995904 | Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS Cancer | Final Rejection | Lantern Pharma Inc. |
| 18249134 | COMBINATIONS OF BCL-2 INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | Non-Final OA | RECURIUM IP HOLDINGS, LLC |
| 18013619 | SALT OF 2-(SUBSTITUTED PYRIMIDINYL) THIAZOLE CARBOXAMIDE COMPOUND, AND COMPOSITION AND USE THEREOF | Non-Final OA | SUNSHINE LAKE PHARMA CO., LTD. |
| 18043269 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | Non-Final OA | CULLGEN (SHANGHAI), INC. |
| 18033167 | INTRANASAL ADMINISTRATION OF SURAMIN FOR TREATING NERVOUS SYSTEM DISORDERS | Non-Final OA | PaxMedica, Inc. |
| 18249228 | Compositions and Uses Thereof | Non-Final OA | Purposeful IKE |
| 18019454 | DRUG COMBINATION AND ITS USE IN THE TREATMENT OF CANCER | Final Rejection | Inderes LTD |
| 18015002 | SATRAPLATIN FOR USE IN THE TREATMENT OF LYMPHOID NEOPLASMS | Final Rejection | pharma& Schweiz GmbH |
| 18013155 | COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Final Rejection | University of Delhi |
| 18011757 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | Non-Final OA | Chengdu Di'ao Jiuhong Pharmaceutical Factory |
| 18009899 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Non-Final OA | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCES |
| 17875368 | PARAXANTHINE-BASED CAFFEINE SUBSTITUTE COMPOSITIONS AND METHOD OF USE THEREOF IN SLOW CAFFEINE METABOLIZERS | Non-Final OA | Ingenious Ingredients, LP |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy